The MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE (MDC) is a member of the Helmholtz Association of National Research Centers, supported by the Federal Government of Germany and the Land Berlin.
For our Molecular Oncology team starting as soon as possible, we are looking for one
ERC-funded Postdoctoral fellow
The position is available in the research group led by Dr. Gaetano Gargiulo at the Max Delbrück Center for Molecular Medicine (MDC, Berlin, D). We seek to recruit an ambitious and self-motivated scientist with interest in molecular mechanisms of homeostasis in cancer.
This project is funded by a European Research Council (ERC) grant and deals with the Glioblastoma Multiforme (GBM). GBM is the most common primary brain tumor and is currently incurable. Tumor heterogeneity and resistance to available treatments affect patients’ clinical management. It is urgent to devise treatments best fitting individual patients (precision medicine) and be able to predict the patients’ response to the chosen therapy. We are approaching these problems by creating and characterizing “humanized” animal models for GBM accurately reflecting patients at molecular level. We aim to exploit these models in state-of-art genetic screens in vivo. The goal of this endeavor is to identify drug targets, molecular biomarkers for response to therapy, and mechanisms of resistance. The lab aims to pursue fundamental research with translational implications in oncology. Our research program focuses on tumor biology and we study genetics, epigenetics and transcriptional control of tumor progression and response to therapy. The group is combining advanced tumor modeling in vivo with genomic, epigenomic and computational approaches. Among others, technologies exploited are: adult stem cells genetic engineering, advanced in vivo tumor modeling, in vivo genetic screens and genome-wide/binding/occupancy/expression profiling by high throughput sequencing and The Cancer Genome Atlas data mining. The postdoctoral researcher will advance the generation, characterization and the use of said models in in vivo genetic screens by combining CRISPR/Cas9 and single cell sequencing technologies.
First and foremost, the desire to make an impact in the field of Molecular Oncology in a friendly, enthusiastic, dedicated and collaborative manner.
The candidate is expected to have a strong background in genetic engineering, molecular and cellular biology and in vivo tumor biology. Past experience with NGS data and statistical skills are desired and hands-on experience with large-scale genetic screening and/or single-cell genomics/transcriptomics is a qualifying skill. An ambitious and sound career plan is an absolute requirement.
• A recent* PhD in Life Sciences obtained in 2018 or expected within the 2019.
• At least one first author high-quality peer-reviewed publication*.
• Excellent spoken and written communication skills in English.
Applications at senior postdoc level (>1 year from PhD) may be considered for candidates with an outstanding track record.
*Manuscript submitted to preprint servers (e.g. bioRxiv.org) will count if also submitted to a high-quality scientific journal for peer-review.
The successful candidate will be initially offered a 2-year contract. A 6-months probation period applies in compliance with the German law. Conditions for extension are simple and will be clarified during the interview.
The salary plus benefits is competitive, commensurate with experience and track record (Salary scale: E13 TVöD/Bund).
The start date is negotiable, within the 2019.
For further information please contact:
Application instructions and contact address: If your profile matches the description, please send your application indicating the registration number 11076/2019 and contact details of two referees, in a single pdf file, by e-mail to firstname.lastname@example.org and please cc Daniela Keyner email@example.com and firstname.lastname@example.org
The applications should be concise (<3 pages, including CV) and highlight the major contributions made by the applicant and elaborate on how the background of the candidate fits the background of the host lab or serve the future projects. In your cover letter, please indicated the ideal starting date.
If you are strongly interested in this position but do not meet one or more criteria, please specifically address in your cover letter in which aspects your skill set, or requirements deviate from the outlined profile.
The MDC is an equal opportunity employer and promotes gender equality. The MDC is committed to raising the proportion of women in science and technology; we thus strongly encourage female researchers and specialists to apply.
MDC postdoctoral researchers benefit from the professional developmental program, which aims to enhance research experiences and career opportunities.
For more information click https://www.mdc-berlin.de/de/content/beruf-und-familie
Key research publications:
Serresi, M., Siteur, B., Hulsman, D., Company, C., Schmitt, M.J., Lieftink, C., Morris, B., Cesaroni, M., Proost, N., et al. and G. Gargiulo (2018). Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities. J Exp Med 215, 3115–3135. http://doi.org/10.1084/jem.20180801
Serresi, M., Gargiulo, G. et al. (2016). Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer. Cancer Cell, 29(1), 17–31. http://doi.org/10.1016/j.ccell.2015.12.006
Gargiulo, G., et al. (2014). In vivo shRNA screens in solid tumors. Nature Protocols, 9(12), 2880–2902. http://doi.org/10.1038/nprot.2014.185
Gargiulo, G., Cesaroni, M., et al. (2013). In vivo RNAi screen for BMI1 targets identifies TGF-β/BMP-ER stress pathways as key regulators of neural- and malignant glioma-stem cell homeostasis. Cancer Cell, 23(5), 660–676. http://doi.org/10.1016/j.ccr.2013.03.030
Gargiulo, G., Levy, S., et al. (2009). NA-Seq: a discovery tool for the analysis of chromatin structure and dynamics during differentiation. Developmental Cell, 16(3), 466–481. http://doi.org/10.1016/j.devcel.2009.02.002